Company Analysis
Sign in

Exelixis, Inc. (EXEL)

Nasdaq: EXEL · Biological Products, (No Diagnostic Substances) · Alameda, CA · filing with the SEC since 2000
Full chart Alerts Compare
Grade7.5
◀ Past 8.6● Present 8.5▶ Future 5.1
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

195 patents granted to the 4 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Exelixis, Inc.’s names, not what it holds today.

Patents granted
195
195 utility, 1976 to Dec 31, 2025
Granted in 2025
8
Against 5 in 2024 and 8 in 2023
Applications published
322
14 of them in 2025
Names they are printed under
4
its own name, a subsidiary
By yearGrantedApplications published
'11'12'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals19
Organic fine chemistry18
Biotechnology1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name4 counted
Exelixis, Inc. its own name
US, as the owner printed on each patent
176 granted
178 published
Exelixis, Inc. its own name
named as the applicant on its applications, in US
0 granted
131 published
Exelixis Patent Company LLC a subsidiary
US, as the owner printed on each patent
13 granted
9 published
Exelixis Plant Sciences, Inc. a subsidiary
US, as the owner printed on each patent
6 granted
4 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Dec 23, 202512,503,438Compounds for the treatment of kinase-dependent disordersOrganic fine chemistryExelixis, Inc.
Dec 16, 202512,497,367Processes for the preparation of a kinase inhibitorOrganic fine chemistryExelixis, Inc.
Dec 2, 202512,486,233Crystalline Solid forms of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of useOrganic fine chemistryExelixis, Inc.
Jul 29, 202512,371,428Pyridone compounds and methods of useOrganic fine chemistryExelixis, Inc.
Apr 15, 202512,275,706Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancerPharmaceuticalsExelixis, Inc.
Apr 1, 202512,264,161Heterocyclic adenosine receptor antagonistsOrganic fine chemistryExelixis, Inc.
Feb 18, 202512,227,481Crystalline solid forms of salts of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of useOrganic fine chemistryExelixis, Inc.
Jan 14, 202512,195,475Compounds for the treatment of kinase-dependent disordersOrganic fine chemistryExelixis, Inc.
Oct 29, 202412,128,039Processes for preparing quinoline compounds and pharmaceutical compositions containing such compoundsPharmaceuticalsExelixis, Inc.
Sep 10, 202412,084,496Anti-ROR antibody constructsBiotechnologyExelixis, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Dec 4, 20252025/0368606CRYSTALLINE FORMS AND SALT FORMS OF A KINASE INHIBITOROrganic fine chemistryExelixis, Inc.
Dec 4, 20252025/0367186C-Met Modulator Pharmaceutical CompositionsPharmaceuticalsExelixis, Inc.
Oct 23, 20252025/03268585T4 BINDING AGENTS AND USES THEREOFBiotechnologyExelixis, Inc.
Sep 25, 20252025/02958035T4 ANTIBODY-DRUG CONJUGATES AND USES THEREOFPharmaceuticalsExelixis, Inc.
Aug 21, 20252025/0262200PROCESSES FOR PREPARING QUINOLINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH COMPOUNDSPharmaceuticalsExelixis, Inc.
Jul 31, 20252025/0243165Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancerPharmaceuticalsExelixis, Inc.
Jun 19, 20252025/0197502MULTISPECIFIC BINDING AGENTS AND USES THEREOFPharmaceuticalsExelixis, Inc.
May 22, 20252025/0163049FUSED BICYCLIC HETEROCYCLYL COMPOUNDS AS USP1 INHIBITORSOrganic fine chemistryExelixis, Inc.
May 1, 20252025/0134880C-MET MODULATOR PHARMACEUTICAL COMPOSITIONSPharmaceuticalsExelixis, Inc.
Mar 27, 20252025/0100966MEK INHIBITORS AND METHODS OF THEIR USEOrganic fine chemistryExelixis, Inc.
What it applied for, 2024 to 2025: Pharmaceuticals 18 · Organic fine chemistry 9 · Biotechnology 3.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton EXEL · research, not advice